Zelluna registers new share capital after equity raises

Zelluna ASA announced the registration of new share capital with the Norwegian Register of Business Enterprises, following a private placement and a retail offering. This registration covers 4,045,413 new shares, including Tranche 1 of the private placement (3,729,774 shares) and 315,639 new shares from the retail offering via PrimaryBid.

The company's new registered share capital is now NOK 24,499,575, divided into 24,499,575 shares, each with a par value of NOK 1. This finalizes a process initiated by the successful private placement of 5,500,000 new shares, announced on November 3, 2025, which included a second tranche of 1,770,226 new shares yet to be registered.

Zelluna ASA is a biotechnology company headquartered in Oslo, Norway, specializing in the development of allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells for cancer treatment. Their lead program, ZI-MA4-1, targeting the MAGE-A4 tumour antigen, is projected to enter clinical trials in 2026.